Mikael Dolsten plans to leave Pfizer after 15 years leading its research and development. This departure leaves a significant gap at the drugmaker, which relies on its pipeline for sales growth. Dolsten joined Pfizer in 2009 through the acquisition of Wyeth. During his tenure, he oversaw the development of successful products such as Ibrance and Eliquis. On Tuesday, Pfizer announced Dolsten’s departure, although he will remain until a successor is in place.
